Nasdaq

European Medicines Agency Validates Type II Variation Application for PADCEV® (enfortumab vedotin) with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Advanced Bladder ...

NEW YORK& TOKYO---- Pfizer Inc. and Astellas Pharma Inc. today announced that on January 26 the European Medicines Agency validated for review a Type II variation application for PADCEV ® with ...
Nasdaq

European Medicines Agency Validates Type II Variation Application for PADCEV™ (enfortumab vedotin) with KEYTRUDA®(pembrolizumab) for First-Line Treatment of Advanced Bladder ...

TOKYO and NEW YORK, Jan. 26, 2024/ PRNewswire/-- Astellas Pharma Inc. and Pfizer Inc. today announced that on Jan. 26, 2024 the European Medicines Agency validated for review a Type II variation ...
WGN-TV

European Medicines Agency Validates Type II Variation Application for PADCEV™ (enfortumab vedotin) with KEYTRUDA®(pembrolizumab) for First-Line Treatment of Advanced Bladder ...

The Type II variation application for first-line use of the combination is based on results from the Phase 3 EV-302 clinical trial (also known as KEYNOTE-A39). The study found the combination improved ...